

Resource Summary Report

Generated by [kravitz2](#) on Aug 10, 2026

CD8 Antibody, anti-human, PE, REAfinity™

RRID:AB_2659235

Type: Antibody

Proper Citation

Miltenyi Biotec Cat# 130-110-678, RRID:AB_2659235

Antibody Information

URL: http://antibodyregistry.org/AB_2659235

Proper Citation: Miltenyi Biotec Cat# 130-110-678, RRID:AB_2659235

Target Antigen: CD8

Host Organism: human

Clonality: monoclonal

Comments: Applications: MACS Flow Cytometry
Antigen Distribution: T cells, NK cells

Antibody Name: CD8 Antibody, anti-human, PE, REAfinity™

Description: This monoclonal targets CD8

Target Organism: human

Clone ID: clone REA734

Antibody ID: AB_2659235

Vendor: Miltenyi Biotec

Catalog Number: 130-110-678

Record Creation Time: 20250819T221315+0000

Record Last Update: 20250820T012956+0000

Ratings and Alerts

No rating or validation information has been found for CD8 Antibody, anti-human, PE, REAfinity™.

No alerts have been found for CD8 Antibody, anti-human, PE, REAfinity™.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 2 mentions in open access literature.

Listed below are recent publications. The full list is available at [kravitz2](#) .

Reinke SM, et al. (2023) Chimeric autoantibody receptor T cells deplete NMDA receptor-specific B cells. Cell, 186(23), 5084.

Grobber Y, et al. (2020) Targeting Indoleamine 2,3-Dioxygenase in Cancer Models Using the Novel Small Molecule Inhibitor NTRC 3883-0. Frontiers in immunology, 11, 609490.